Eli Lilly and Stock Forecast for 2022 - 2025 - 2030
Updated on 05/28/2022
Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by twelve distinguished experts, with an average mark of $321.00. If it reached this goal, it would represent a potential downside of approximately -0.77% from the previous closing price in May, 2022. The high end is $369.00, and the low is $202.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
-0.77% Downside
Eli Lilly and Fair Value Forecast for 2022 - 2025 - 2030
Eli Lilly and's Fair Value has seen considerable growth in the last three years, going from $118.22 to $173.81 – a gain of 47.03% In the next year, analysts believe that Fair Value will reach an unimpressive $184.67 – an increase of 6.25% For the next nine years, the forecast is for Fair Value to grow by 148.04%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
12
|
$181.09 | $187.12 | 2.71% | 16 |
| ROG Stock Forecast | Roche Holding | Outperform |
0
|
CHF346.20 | CHF384.23 | 12.94% | 20 |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$150.00 | $164.23 | 11.83% | 19 |
| MRK Stock Forecast | Merck | Outperform |
6
|
$93.08 | $91.73 | 2.06% | 19 |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
18
|
$572.35 | $683.53 | 19.94% | 15 |
Eli Lilly and Revenue Forecast for 2022 - 2025 - 2030
Eli Lilly and's Revenue has seen considerable growth in the last three years, going from $21.49B to $28.32B – a gain of 31.75% In the next year, analysts believe that Revenue will reach an unimpressive $28.51B – an increase of 0.66% For the next nine years, the forecast is for Revenue to grow by 69.31%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£105.80 | £136.08 | 37.87% | 13 |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$116.69 | $141.24 | 19.98% | 19 |
| NOVN Stock Forecast | Novartis | Outperform |
0
|
CHF77.22 | CHF103.75 | 19.24% | 12 |
Eli Lilly and Dividend per Share Forecast for 2022 - 2025 - 2030
In three years, DPS for Eli Lilly and has grown by a whopping 51.11%, going from $2.25 to $3.40. In the coming year, analysts are expecting a moderate increase in DPS, predicting it will reach $3.78 – an increase of 11.18%. Over the next nine years, experts anticipate that DPS growth for Eli Lilly and will be 252.65%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$76.14 | $76.69 | 5.07% | 16 |
| SAN Stock Forecast | Sanofi | Outperform |
18
|
103.72€ | 104.66€ | 10.13% | 20 |
| AMGN Stock Forecast | Amgen | Hold |
7
|
$255.26 | $246.46 | -2.06% | 13 |
Eli Lilly and Free Cash Flow Forecast for 2022 - 2025 - 2030
Over the last three years, Eli Lilly and's Free Cash Flow has increased by 37.95%, going from $4.31B to $5.95B. In the next year, analysts are expecting a moderate increase in EPS, predicting it will reach $7.76B – an increase of 30.41%. The 2030 forecast is for Free Cash Flow to reach $15.12B or grow by 154.09%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GlaxoSmithKline | Outperform |
16
|
£17.33 | £16.08 | 3.87% | 11 |
| CSL Stock Forecast | CSL | Outperform |
0
|
$266.28 | $228.01 | -14.01% | 10 |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
18
|
178.20€ | 147.51€ | 17.85% | 15 |
Eli Lilly and Net Income Forecast for 2022 - 2025 - 2030
Eli Lilly and's Net Income has seen major growth over the last three years, jumping from $3.23B to $5.58B – an increase of 72.7%. In the next year, analysts predict that Net Income will reach a reasonable $7.88B – an increase of 41.25%. For the next nine years, the forecast is for Net Income to grow by 211.18%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences | Outperform |
11
|
$64.80 | $75.96 | 6.48% | 19 |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$172.10 | $235.45 | 45.26% | 13 |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$692.80 | $696.64 | 1.04% | 14 |
Eli Lilly and EBITDA Forecast for 2022 - 2025 - 2030
In the past three years, Eli Lilly and's EBITDA has seen a tremendous growth rate, increasing from $7.63B to $9.73B – an increase of 27.38%. For next year, the 12.00 analysts predict earnings per share of $10.44B, which would mean an increase of 7.3%. Over the next nine years, the pros' prediction is EBITDA of $20.45B, which would mean a 9-year growth forecast of 110.29%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$256.46 | $270.20 | 11.13% | 3 |
| BAYN Stock Forecast | Bayer | Outperform |
16
|
66.58€ | 67.79€ | 14.15% | 14 |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.79k | ¥0.00 | 18.73% | 0 |
Eli Lilly and EBIT Forecast for 2022 - 2025 - 2030
Eli Lilly and's EBIT has increased by 35.71% in the last three years, going from $6.03B to $8.18B. In the next year, analysts expect EBIT to reach a reasonable $9.13B – an increase of 11.7%. For the next nine years, the forecast is for EBIT to grow by 143.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
0
|
¥3.11k | ¥0.00 | 28.53% | 0 |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$76.16 | $89.29 | 18.17% | 3 |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$206.20 | $287.21 | 10.33% | 24 |
Eli Lilly and EPS Price Prediction Forecast for 2022 - 2025 - 2030
Eli Lilly and's EPS has seen considerable growth in the last three years, going from $5.55 to $8.16 – a gain of 47.03% In the next year, analysts believe that EPS will reach an unimpressive $8.67 – an increase of 6.25% For the next nine years, the forecast is for EPS to grow by 148.04%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
0
|
¥1.80k | ¥0.00 | 33.33% | 0 |
| 4507 Stock Forecast | Shionogi & | Outperform |
0
|
¥7.81k | ¥0.00 | 12.43% | 0 |
| FME Stock Forecast | Fresenius Medical Care AG & Co... | Hold |
18
|
56.58€ | 80.66€ | 15.43% | 11 |